about
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer.Severe thrombocytopenia related to long-term trastuzumab exposure.Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.SEOM clinical guidelines in metastatic breast cancer 2015.SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.Novel biomarkers in primary breast core biopsies to predict poor response to neoadjuvant chemotherapy and appearance of metastases.HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study.Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer.Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma.Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study.Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trialReal-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimensClinical Impact of 18F-FDG-PET in the Suspicion of Recurrent Ovarian Carcinoma Based on Elevated Tumor Marker Serum LevelsSafety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trialA Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast CancerAnticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexiaPegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE studyRandomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast CancerHER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeEvaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trialsCirculating tumor cells (CTCs) and cytokeratin 19 (CK19) mRNA as prognostic factors in heavily pretreated patients with metastatic breast cancerRandomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial)Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
P50
Q33349736-51A8050E-CD00-4919-ABD2-B7BF682CADD2Q33362178-CA54E3AA-F73C-43CD-86A0-D7B6C4BCDAC9Q33406781-77DBF232-66C8-4EED-82CD-BD53DD31F56EQ33591751-3064704D-7A2A-49F6-91AC-E507DCD1596FQ33925164-4EA79988-2165-440B-BB22-5047655C3F59Q36400360-95ABFB76-CD58-402D-BE66-09140AAA0EFEQ37148642-76FEDBF3-781F-421D-8DB3-5D55D60C947CQ37180350-E2B47706-3558-4275-9672-D540FA7276D5Q38788733-2C29791C-B371-4BBC-8589-69F1DC780637Q42506198-6BFBE8B8-BC43-431A-B330-9B271ADDA32FQ44616783-369B2A44-B29E-4862-89B0-3864CAFC48B9Q44971706-C4E164E4-64DF-4D50-93FE-45058A9715D4Q45025790-514B1996-EE8D-47E2-9248-CBCE3CCBE660Q46616923-417BE6C6-033E-42F3-8118-AAA0B1BDC1D8Q47572918-1E735FD3-D9C7-46F4-91D6-1A7B27C523F2Q47582481-07CFB439-A2F9-40A8-973D-2B30C3D26217Q47794448-D6A4FA95-5CC1-4168-BD7A-5813F06ED104Q52869619-E29E9222-2607-46E8-9FA2-0F11C0A1A17AQ57110471-7425B77F-77CF-489F-B9AC-ED0ADF35FE76Q57183295-B1BDEAA8-EF92-4240-8429-59BC9EAB9BEFQ57219558-805631F8-B367-402E-8F95-7FC691BDF393Q60913102-D441101C-9E71-4E67-BACA-604E4D57B35CQ64085234-BF9C72FC-85C5-4CCD-8600-B9B83A36BCF4Q77108177-A1DB449D-2058-440E-B6B1-A49DFEBEFA58Q87322576-EDAA04E2-FCAC-405A-8F85-90DF8C4E163DQ90615925-91BBA26C-CCAE-463F-87EC-A55B2B7DBCF5Q91626887-ABE7A914-56DA-4A75-A45F-792397CFFC0FQ91654261-A5BAC499-F377-4816-A1BB-A28173D5766AQ91828375-B20FA950-55E7-47C2-8B11-BB25785A0926Q91893972-27CD619E-45C4-4459-AE69-BE1CDF5BE85AQ92782415-CA524200-BC97-455F-BDC0-CEAA7DC33957
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
S Morales
@ast
S Morales
@en
S Morales
@es
S Morales
@nl
type
label
S Morales
@ast
S Morales
@en
S Morales
@es
S Morales
@nl
prefLabel
S Morales
@ast
S Morales
@en
S Morales
@es
S Morales
@nl
P106
P31
P496
0000-0001-7445-4193